Barclays Downgrades Forte Biosciences Inc. (FBRX) to Equalweight

July 28, 2026 3:34 AM

Barclays analyst Etzer Darout downgraded Forte Biosciences Inc. (NASDAQ: FBRX) from Overweight to Equalweight with a price target of $77.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found